Which has stronger earnings & valuation, TMDX or SIBN?

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 4.87 $190.29M $3.89 21.93 SiBone $200.93M 4.10 -$18.90M -$0.34 N/A

Does the media favor TMDX or SIBN?

In the previous week, TransMedics Group had 4 more articles in the media than SiBone. MarketBeat recorded 6 mentions for TransMedics Group and 2 mentions for SiBone. SiBone's average media sentiment score of 1.77 beat TransMedics Group's score of 0.54 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, SIBN or ATRC?

AtriCure has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.10 -$18.90M -$0.34 N/A AtriCure $534.53M 5.56 -$11.45M $0.21 278.00

Is SIBN or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to SiBone's net margin of -6.85%. AtriCure's return on equity of 2.34% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% AtriCure 1.85% 2.34% 1.77%

Does the media prefer SIBN or ATRC?

In the previous week, AtriCure had 8 more articles in the media than SiBone. MarketBeat recorded 10 mentions for AtriCure and 2 mentions for SiBone. SiBone's average media sentiment score of 1.77 beat AtriCure's score of 0.73 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AtriCure 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, BFLY or SIBN?

SiBone has higher revenue and earnings than Butterfly Network. SiBone is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Butterfly Network $97.61M 25.73 -$77.06M -$0.29 N/A SiBone $200.93M 4.10 -$18.90M -$0.34 N/A

Does the media prefer BFLY or SIBN?

In the previous week, Butterfly Network had 13 more articles in the media than SiBone. MarketBeat recorded 15 mentions for Butterfly Network and 2 mentions for SiBone. SiBone's average media sentiment score of 1.77 beat Butterfly Network's score of 0.49 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, SIBN or AXGN?

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.10 -$18.90M -$0.34 N/A AxoGen $251.17M 9.29 -$15.70M -$0.68 N/A

Is SIBN or AXGN more profitable?

SiBone has a net margin of -6.85% compared to AxoGen's net margin of -13.36%. SiBone's return on equity of -8.23% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% AxoGen -13.36% -8.90% -6.47%

Does the media prefer SIBN or AXGN?

In the previous week, AxoGen had 5 more articles in the media than SiBone. MarketBeat recorded 7 mentions for AxoGen and 2 mentions for SiBone. SiBone's average media sentiment score of 1.77 beat AxoGen's score of 0.30 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AxoGen 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ESTA or SIBN more profitable?

SiBone has a net margin of -6.85% compared to Establishment Labs' net margin of -15.82%. SiBone's return on equity of -8.23% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Establishment Labs -15.82% -196.69% -10.73% SiBone -6.85% -8.23% -6.07%

Does the media refer more to ESTA or SIBN?

In the previous week, Establishment Labs had 4 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Establishment Labs and 2 mentions for SiBone. SiBone's average media sentiment score of 1.77 beat Establishment Labs' score of 0.76 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

SiBone (SIBN) Competitors

$18.59 +0.07 (+0.38%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$18.59 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

Compare

SIBN vs. TMDX, ATRC, BFLY, AXGN, and ESTA

Should you buy SiBone stock or one of its competitors? SiBone's main competitors and comparable companies include TransMedics Group (TMDX), AtriCure (ATRC), Butterfly Network (BFLY), AxoGen (AXGN), and Establishment Labs (ESTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does SiBone compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and SiBone (NASDAQ:SIBN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

In the previous week, TransMedics Group had 4 more articles in the media than SiBone. MarketBeat recorded 6 mentions for TransMedics Group and 2 mentions for SiBone. SiBone's average media sentiment score of 1.77 beat TransMedics Group's score of 0.54 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.87	$190.29M	$3.89	21.93
SiBone	$200.93M	4.10	-$18.90M	-$0.34	N/A

TransMedics Group presently has a consensus target price of $121.10, suggesting a potential upside of 41.99%. SiBone has a consensus target price of $24.17, suggesting a potential upside of 30.00%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

TransMedics Group has a net margin of 22.69% compared to SiBone's net margin of -6.85%. TransMedics Group's return on equity of 15.88% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
SiBone	-6.85%	-8.23%	-6.07%

TransMedics Group has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Summary

TransMedics Group beats SiBone on 13 of the 16 factors compared between the two stocks.

How does SiBone compare to AtriCure?

SiBone (NASDAQ:SIBN) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

AtriCure has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.10	-$18.90M	-$0.34	N/A
AtriCure	$534.53M	5.56	-$11.45M	$0.21	278.00

AtriCure has a net margin of 1.85% compared to SiBone's net margin of -6.85%. AtriCure's return on equity of 2.34% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
AtriCure	1.85%	2.34%	1.77%

In the previous week, AtriCure had 8 more articles in the media than SiBone. MarketBeat recorded 10 mentions for AtriCure and 2 mentions for SiBone. SiBone's average media sentiment score of 1.77 beat AtriCure's score of 0.73 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
AtriCure	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.1% of SiBone shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

SiBone has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

SiBone currently has a consensus price target of $24.17, suggesting a potential upside of 30.00%. AtriCure has a consensus price target of $53.30, suggesting a potential downside of 8.70%. Given SiBone's higher possible upside, analysts plainly believe SiBone is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

AtriCure beats SiBone on 14 of the 16 factors compared between the two stocks.

How does SiBone compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and SiBone (NASDAQ:SIBN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

SiBone has a net margin of -6.85% compared to Butterfly Network's net margin of -66.74%. SiBone's return on equity of -8.23% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
SiBone	-6.85%	-8.23%	-6.07%

SiBone has higher revenue and earnings than Butterfly Network. SiBone is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	25.73	-$77.06M	-$0.29	N/A
SiBone	$200.93M	4.10	-$18.90M	-$0.34	N/A

Butterfly Network has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

In the previous week, Butterfly Network had 13 more articles in the media than SiBone. MarketBeat recorded 15 mentions for Butterfly Network and 2 mentions for SiBone. SiBone's average media sentiment score of 1.77 beat Butterfly Network's score of 0.49 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

37.9% of Butterfly Network shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 22.0% of Butterfly Network shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Butterfly Network presently has a consensus target price of $7.25, suggesting a potential downside of 23.13%. SiBone has a consensus target price of $24.17, suggesting a potential upside of 30.00%. Given SiBone's stronger consensus rating and higher possible upside, analysts clearly believe SiBone is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

SiBone beats Butterfly Network on 10 of the 16 factors compared between the two stocks.

How does SiBone compare to AxoGen?

SiBone (NASDAQ:SIBN) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

SiBone has a net margin of -6.85% compared to AxoGen's net margin of -13.36%. SiBone's return on equity of -8.23% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
AxoGen	-13.36%	-8.90%	-6.47%

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.10	-$18.90M	-$0.34	N/A
AxoGen	$251.17M	9.29	-$15.70M	-$0.68	N/A

SiBone has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

In the previous week, AxoGen had 5 more articles in the media than SiBone. MarketBeat recorded 7 mentions for AxoGen and 2 mentions for SiBone. SiBone's average media sentiment score of 1.77 beat AxoGen's score of 0.30 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
AxoGen	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.1% of SiBone shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SiBone currently has a consensus target price of $24.17, indicating a potential upside of 30.00%. AxoGen has a consensus target price of $52.11, indicating a potential upside of 20.10%. Given SiBone's higher probable upside, analysts plainly believe SiBone is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

SiBone beats AxoGen on 9 of the 16 factors compared between the two stocks.

How does SiBone compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and SiBone (NASDAQ:SIBN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Establishment Labs currently has a consensus target price of $100.25, suggesting a potential upside of 51.96%. SiBone has a consensus target price of $24.17, suggesting a potential upside of 30.00%. Given Establishment Labs' stronger consensus rating and higher possible upside, research analysts clearly believe Establishment Labs is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Establishment Labs has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

SiBone has a net margin of -6.85% compared to Establishment Labs' net margin of -15.82%. SiBone's return on equity of -8.23% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
SiBone	-6.85%	-8.23%	-6.07%

SiBone has lower revenue, but higher earnings than Establishment Labs. SiBone is trading at a lower price-to-earnings ratio than Establishment Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	9.31	-$51.06M	-$1.31	N/A
SiBone	$200.93M	4.10	-$18.90M	-$0.34	N/A

In the previous week, Establishment Labs had 4 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Establishment Labs and 2 mentions for SiBone. SiBone's average media sentiment score of 1.77 beat Establishment Labs' score of 0.76 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by company insiders. Comparatively, 4.0% of SiBone shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Establishment Labs beats SiBone on 9 of the 16 factors compared between the two stocks.

Get SiBone News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIBN vs. The Competition

Export

Metric	SiBone	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$821.35M	$5.54B	$7.29B	$13.11B
Dividend Yield	N/A	1.80%	2.52%	13.50%
P/E Ratio	-54.68	25.31	275.84	25.78
Price / Sales	4.10	44.45	614.77	83.70
Price / Cash	N/A	32.96	79.23	52.93
Price / Book	4.55	5.77	10.44	6.30
Net Income	-$18.90M	$151.55M	$3.51B	$360.35M
7 Day Performance	2.76%	-0.97%	-1.31%	-0.23%
1 Month Performance	-4.32%	-4.82%	-4.72%	-3.87%
1 Year Performance	32.31%	7.60%	14.96%	5.38%

SiBone Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIBN SiBone	2.8711 of 5 stars	$18.59 +0.4%	$24.17 +30.0%	+31.5%	$821.35M	$200.93M	N/A	376	Positive News
TMDX TransMedics Group	4.5449 of 5 stars	$88.09 +0.9%	$121.10 +37.5%	-25.1%	$3.05B	$605.49M	22.67	898	Options Volume
ATRC AtriCure	2.4119 of 5 stars	$59.44 +1.9%	$53.30 -10.3%	+66.7%	$3.02B	$534.53M	282.81	1,350	News Coverage Insider Trade
BFLY Butterfly Network	1.5179 of 5 stars	$9.74 +19.7%	$7.25 -25.6%	+382.5%	$2.62B	$97.61M	N/A	220	News Coverage Analyst Forecast High Trading Volume
AXGN AxoGen	3.0385 of 5 stars	$44.56 -3.0%	$51.56 +15.7%	+156.4%	$2.40B	$225.21M	N/A	622	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIBN) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SiBone (SIBN) Competitors

SIBN vs. TMDX, ATRC, BFLY, AXGN, and ESTA

How does SiBone compare to TransMedics Group?

Summary

How does SiBone compare to AtriCure?

Summary

How does SiBone compare to Butterfly Network?

Summary

How does SiBone compare to AxoGen?

Summary

How does SiBone compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SiBone (SIBN) Competitors

SIBN vs. TMDX, ATRC, BFLY, AXGN, and ESTA

How does SiBone compare to TransMedics Group?

Does the media favor TMDX or SIBN?

Which has stronger earnings & valuation, TMDX or SIBN?

Do analysts recommend TMDX or SIBN?

Do insiders & institutionals hold more shares of TMDX or SIBN?

Is TMDX or SIBN more profitable?

Which has more volatility and risk, TMDX or SIBN?

Summary

How does SiBone compare to AtriCure?

Which has better valuation & earnings, SIBN or ATRC?

Is SIBN or ATRC more profitable?

Does the media prefer SIBN or ATRC?

Do insiders & institutionals have more ownership in SIBN or ATRC?

Which has more risk and volatility, SIBN or ATRC?

Do analysts prefer SIBN or ATRC?

Summary

How does SiBone compare to Butterfly Network?

Is BFLY or SIBN more profitable?

Which has higher valuation and earnings, BFLY or SIBN?

Which has more risk & volatility, BFLY or SIBN?

Does the media prefer BFLY or SIBN?

Do institutionals and insiders have more ownership in BFLY or SIBN?

Do analysts prefer BFLY or SIBN?

Summary

How does SiBone compare to AxoGen?

Is SIBN or AXGN more profitable?

Which has higher valuation and earnings, SIBN or AXGN?

Which has more volatility and risk, SIBN or AXGN?

Does the media prefer SIBN or AXGN?

Do insiders and institutionals hold more shares of SIBN or AXGN?

Do analysts recommend SIBN or AXGN?

Summary

How does SiBone compare to Establishment Labs?

Do analysts recommend ESTA or SIBN?

Which has more risk & volatility, ESTA or SIBN?

Is ESTA or SIBN more profitable?

Which has better valuation and earnings, ESTA or SIBN?

Does the media refer more to ESTA or SIBN?

Do insiders & institutionals hold more shares of ESTA or SIBN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools